Robbins Arroyo LLP Is Investigating the Officers and Directors of American Renal Associates Holdings, Inc. (ARA) on Behalf of Shareholders

Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of American Renal Associates, Inc. ARA breached their fiduciary duties to shareholders. On August 31, 2016, a class action complaint was filed against American Renal Associates ("ARA") in the U.S. District Court for the Southern District of New York for alleged violations of the Securities Act of 1933 and the Securities Exchange Act of 1934. The complaint alleges that ARA engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act plans to obtain greater reimbursement for the company's dialysis services. ARA operates as a dialysis services provider in the U.S. and focuses exclusively on joint venture partnerships with physicians.

View this press release on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/american-renal-associates-holdings-inc-nov-2017

American Renal Associates Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!